OBJECTIVE: To determine the prevalence of grade 3 or 4 @entity137 associated with intraperitoneal (IP) chemotherapy subsequent to primary surgical debulking compared to post-neoadjuvant chemotherapy and interval debulking in advanced @entity43 . METHODS: @entity1 receiving IP chemotherapy from 2006 to 2010 were reviewed. Study cohort was stratified by initial treatment (upfront surgery vs neoadjuvant chemotherapy). The National Cancer Institute @entity137 grading scale was used to assess treatment-related @entity137 immediately before each cycle. The      test was used to check for association between categorical variables. RESULTS: Thirty-three @entity1 received IP chemotherapy after optimal debulking. Sixteen @entity1 had upfront surgery. The total number of IP chemotherapy cycles administered was 134. Significantly, more @entity1 treated with IP chemotherapy after intravenous neoadjuvant chemotherapy experienced @entity1295 (P=0.038) compared to those treated after upfront surgery. During the course of IP regimen, the @entity1 having upfront surgery tended to experience more grade 3/4 hematologic @entity137 (P=0.06) and @entity490 (P=0.08). Twenty-four (73%) of 33 @entity1 completed all prescribed IP chemotherapy cycles. There was no significant difference between the 2 groups in need for dose reduction or delays, use of @entity1311 on day 8, @entity344 , and IP port complications. CONCLUSIONS: Intraperitoneal chemotherapy can be given after optimal primary surgery or interval surgery after neoadjuvant chemotherapy with similar @entity137 profile. @entity137 data can be used to plan for optimal IP chemotherapy delivery, @entity1 counseling, and ongoing supportive care.

Comparative study of grade 3/4 XXXX associated with intraperitoneal chemotherapy administered after primary versus interval surgical debulking in @entity43 .

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity', 'toxicities'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity344 :: ('MESH:D005767', 'Disease') :: ['neurologic/gastrointestinal/metabolic toxicities'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
